In fact, in patients with HER2+ metastatic breast tumors, with complete or partial remission, upon treatment with preoperative trastuzumab, tumor infiltration of lymphoid cells was identified along with ex-vivo ADCC activity in the presence of PMBCs. This evidence concerns the gene ERBB2 and neoplasm.